LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D. has been appointed Executive Vice President of Operations and Chief Scientific Officer.